Compare Pfizer Inc (PFE) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs TKO Group Holdings Inc — how do they compare? Pfizer Inc trades at $27.74 (market cap $159.59B), while TKO Group Holdings Inc trades at $181.62 (market cap $13.06B). The key difference: Pfizer Inc is far larger — about 12.2× TKO Group Holdings Inc's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and TKO Group Holdings Inc for 30 Days on average.
| PFE | TKO | |
|---|---|---|
Market Cap | $159.59B | $13.06B |
Volume | 30,937,010 | 999,906 |
Sector | Health | Media |
52-Week High | $29.02 | $224.96 |
52-Week Low | $23.67 | $175.58 |
Typical Hold Time | 158 Days | 30 Days |
Enterprise Value | $211.09B | $17.42B |
Dividend Yield | 6.14% | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
TKO trades at $178.64, down 1.24% on the day and near a 52-week low of $174.58 (Defense World, 2026-10-02). The stock is technically bearish with mixed earnings, missing Q2 2026 EPS estimates but beating Q1. Revenue growth is solid, with 2026 guidance raised to $5.3B, though high P/E of 62.68 signals premium valuation. A quarterly dividend of $0.79 was declared for September 2026.
Outlook is supported by strong analyst consensus (89% buy ratings) and a $227 price target, but risks include recent technical weakness, margin pressure, and competitive threats. The stock offers upside if media rights and live event execution drive earnings growth, yet volatility near lows warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
